2008: RA Treatment: Small Molecules and Gene Therapy
Search or Browse by Day

RA Treatment: Small Molecules and Gene Therapy

Sunday, October 26, 2008
714
A Randomized Placebo-Controlled Study of INCB018424, a Selective Janus Kinase1& 2 (JAK1&2) Inhibitor in Rheumatoid Arthritis (RA)
715
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of an Oral p38α MAPK Inhibitor, SCIO-469, in Patients with Active Rheumatoid Arthritis
716
CP-690,550, an Oral JAK Inhibitor, is a Well-tolerated and Effective Long-term Treatment for Patients with Moderate to Severe Rheumatoid Arthritis
717
In Early RA, Patients with a Good Initial Response to MTX Monotherapy Continue to have Excellent Clinical Outcomes during the First Year of Therapy
718
Multinational Evidence-based Recommendations for the Use of Methotrexate in Rheumatic Disorders: Integrating Systematic Literature Research and Expert Opinion of a Broad Panel of Rheumatologists in the 3E Initiative
719
Safety and Clinical Outcomes after Intra-articular Administration of a Recombinant Adeno-Associated Vector Containing a TNF Antagonist Gene
See more of: ACR Abstract Submission ACR Concurrent Abstract Session
<< Previous Session Level | Next Session Level >>